{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-003196","form_type":"8-K","ticker":null,"cik":"0001444380","company_name":"NEVRO CORP","filed_at":"2024-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.211888+00:00","generated_at":"2026-06-07T01:25:42.793998+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nevro Q4 prelim revenue $116M (+2% YoY) beats expectations; cuts 5% of staff","bullets":["Preliminary Q4 2023 worldwide revenue ~$116.0M, up 2% YoY, exceeding company expectations.","Full-year 2023 revenue ~$425.0M (+5% YoY); PDN sales $77.9M (+63% YoY).","Restructuring approved: lay off 63 employees (5% workforce), mainly internal roles.","Expects $14M-$15M positive impact on 2024 adjusted EBITDA; $5M-$6M charge in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-003196","json":"https://secwatch.observer/filing/0000950170-24-003196.json","markdown":"https://secwatch.observer/filing/0000950170-24-003196.md","text":"https://secwatch.observer/filing/0000950170-24-003196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/0000950170-24-003196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/nvro-20240106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:25:42.793998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d74d80fd28869f5c58db5e00e042d9f03177e28","claim":"NEVRO CORP reported preliminary financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On January 9, 2024, Nevro Corp. (\"Nevro\" or the \"Company\") issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/0000950170-24-003196-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"21f16aeac0bf21191bd63a3772e710dd0f632a03","claim":"NEVRO CORP announced a restructuring with charges of $5 million to $6 million restructuring charge affecting corporate, sales and marketing, and operations positions but largely focused on internally facing roles (63 employees, which represented approximately 5% of the Company’s total number of employees).","evidence_excerpt":"expense increases, including inflation, merit increases and other acquisition-related expenses. In addition, GAAP operating expenses in the first quarter of 2024 will reflect a $5 million to $6 million restructuring charge, consisting of one-time severance and other termination benefit costs. The Company expects that the Restructuring, including related cash","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444380/000095017024003196/0000950170-24-003196-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$5 million to $6 million restructuring charge"},{"label":"Affected area","value":"corporate, sales and marketing, and operations positions but largely focused on internally facing roles"},{"label":"Headcount","value":"63 employees, which represented approximately 5% of the Company’s total number of employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}